TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Total number of minutes per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in Total Acne Lesions Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Muscle Sympathetic Nerve Activity (MSNA) Burst Frequency at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Baroreflex Sensitivity (BRS) at Rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in MSNA Burst Frequency While Under Mental Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in BRS While Under Mental Stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of the Development of Blistering
Endpoint domain: Adverse events/effects
Primary endpoint: Partner notification
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Repeat Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Pulmonary Capillary Blood Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diffusing Capacity for Carbon Monoxide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sensitivity and specificity of breath ammonia measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Coronary artery flow using TIMI flow grade after stent implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Coronary TIMI frame count after stent implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Slow flow / no-reflow phenomenon after stent implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bowel purity degree
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subjective Stress Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual food choice
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: induced sputum eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Subjective Emotional Arousal Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Full-mouth plaque score (FMPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of risks and benefits of procedures
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Curve From Time 0 to Infinity (AUC0-inf) of Islatravir (ISL) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of ISlatravir (ISL) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Terminal Half-Life (t½) of Islatravir (ISL) in Plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pathologic Complete Response (CR) after Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Liver iron content and stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: physical violence
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of MCP-1 -2518 A/G and CCR2 -190 G/A gene polymorphisms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Confirmed Diagnosis of NAION
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Active delivery status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in NAFLD activity Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of completed goals of care designation form
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Ankle Passive Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biopsy-proven acute/chronic rejection
Endpoint domain: Adverse events/effects
Primary endpoint: Chronic lower abdominal and/or pelvic pain
Endpoint domain: Adverse events/effects
Primary endpoint: Abnormal uterine bleeding (AUB)
Endpoint domain: Adverse events/effects
Primary endpoint: New onset or worsening allergic/hypersensitivity reactions and autoimmune disorders
Endpoint domain: Adverse events/effects
Primary endpoint: Step time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breath Carbon Monoxide Levels Indicating Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absorption fraction of D-xylose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal Memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: IC TFV-DP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation-induced DNA double-strand breaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage time of intragastric pH<4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary Patency Rate
Endpoint domain: Mortality/survival
Primary endpoint: Amputation-Free Survival at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: 2-grade response: PA-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-grade response: SA-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-grade response: PA-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-grade response: SA-SMFRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhanced T Lymphocyte Immune Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bioavailability of Silibinin vs Sylimarin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Ischemic stroke / Systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Healthcare resource consumption
Endpoint domain: Resource use
Primary endpoint: Change From Baseline Shoulder Pain Intensity at End of Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Device Related Adverse Event Rates
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of lymphocele post kidney transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Iron Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum Ferritin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythrocyte Zinc Protoporphyrin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Portal venous flow findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of escalating doses of NGR-hTNF
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of sickle cell related severe complications leading to hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of cardiac amyloidosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Events of Special Interest
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis of endoleak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adjudicated Overall Malignant Neoplasms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Liver-related HBV Disease Progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: urinary post cystography infection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Perometric Relative Arm Volume Change (RVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success defined as symptomatic and endoscopic improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Posterior cross bite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Anterior open bite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Change from baseline number of endocrine disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Arrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to tumor progression (TTP)
Endpoint domain: Mortality/survival
Primary endpoint: Number and severity of treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Blood sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: durations of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total Score for Kidney-Disease Quality of Life Short Form v1.3
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent of patients who maintained stable vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in best-corrected visual acuity at Month 24 from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: abnormal white matter changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sexual Minority Adolescent Stress Inventory (SMASI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Coping Strategies Inventory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Adapted CSSRS Suicide Questions (Columbia Suicide Severity Rating Scale)
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter Tip Colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Time to contralateral gate cannulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Necitumumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Cmax of Gemcitabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dose-Normalized Cmax of Cisplatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of biologically active tumor tissue from therapy-related changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety (side-effects or complications related to the study drug)
Endpoint domain: Adverse events/effects
Primary endpoint: Immune Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific Arixtra® concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a Grade 3 or greater adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of a Grade 1 or greater adverse event of specific conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of HIV-1 Gag-specific CD8 T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HIV-1 RNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Disability after a stroke
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients with adverse events after treatment with Melphalan/HDS
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with adverse events after treatment with Sorafenib following treatment with Melphalan/HDS
Endpoint domain: Adverse events/effects
Primary endpoint: Progression free survival in months of patients receiving Melphalan/HDS treatment followed by Sorafenib
Endpoint domain: Mortality/survival
Primary endpoint: newborn hearing screening results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overt hepatic encephalopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 28 days' mortality
Endpoint domain: Mortality/survival
Primary endpoint: Findings of musculoskeletal ultrasonography and elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Total anesthesia-related time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Effect of pimavanserin on Tourette Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral blood differential count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: lung functional tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: single breath carbon monoxide diffusing capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of SNPs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Percent Predicted Forced Vital Capacity (FVC) at Week 105
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Mean Distance Walked in the 6-minute Walk Test (6MWT) at Week 105
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gallbladder ejection fraction (EF%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of children completing developmental testing
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of incidences of adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients with a best overall response of Complete Response (CR) or Partial Response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normalization of glucose metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microvascular density in oral mucosa and skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular Perfusion in oral mucosa and skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart's respiratory value at H6 post ICU admission
Endpoint domain: Mortality/survival
Primary endpoint: Change in WSAS
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: drop in oxygen saturation during deep inspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cancer completion for all eligible cancers
Endpoint domain: Mortality/survival
Primary endpoint: Immediate Sensitivity Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tactile Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Air Blast Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of dyspeptic or complicated ulcer/erosions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Toxicity of chemotherapy and radiotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of the written patient educational materials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Validation that the goals of the educational-intervention instruction are being achieved
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Who Developed Anti-romosozumab Antibodies
Endpoint domain: Adverse events/effects
Primary endpoint: Lille Apathy Rating Scale (LARS) score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ratio of Peak Plasma Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Area under the plasma concentration versus time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 16 weeks progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Objective response rate - immune checkpoint (ORR-IC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improved Antioxidant Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Self-report Craving level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % change in craving and control related neural activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Smoking
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under the plasma concentration versus time curve (AUC(0-t))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of T-DOC® 5 Fr Catheters
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of T-DOC® 5 Fr Catheters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: clinical improvement of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Residual Volume (RV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Microvascular
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Association of low physical activity with risk of T2D
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPS-induced TNF-alpha production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: concentration of glycerol in capillary blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Subjects With rSBA-MenA, rSBA-MenC, rSBA-MenW-135 and rSBA-MenY Titers ≥ the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-HBs Concentrations ≥ the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-PRP Concentrations ≥ the Cut-off
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Letter Number Sequencing task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Montreal Cognitive Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: 1-n-back task
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in TGFB1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Event-Related Potentials (ERPs) during PSST task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: [11C]raclopride binding potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Systolic Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Natriuresis (Urinary Sodium Excretion) at 60 Minutes for Preclinical Diastolic Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: 30 Day Freedom From Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Perioperative Freedom From Device/Procedure Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Technical Success Rate of B-Laser™ Catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pupil dilations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing a Venous Thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Proportion of Follicular Helper T cells in the blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes